Cortexyme, Inc. Announces Closing of Initial Public Offering and the Exercise of the Underwriters’ Option to Purchase Additional Shares
A registration statement relating to these securities has been filed
BofA Merrill Lynch, NC1-004-03-43,
200 North College Street, 3rd Floor, Charlotte, NC28255-0001, Attention: Prospectus Department, or by phone at 1-800-294-1322 or by email at email@example.com; Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, Eleven Madison Avenue, 3rd Floor, New York, NY10010, by telephone at 1-800-221-1037 or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of shares of Cortexyme’s common stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Statements in this press release contain “forward-looking statements”
that are subject to substantial risks and uncertainties. Forward-looking
statements contained in this press release may be identified by the use
of words such as “anticipate,” “expect,” “believe,” “will,” “may,”
“should,” “estimate,” “project,” “outlook,” “forecast” or other similar
words. Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future events
that may not prove to be accurate. Factors that could cause actual
results to differ include, but are not limited to, the risks and
uncertainties described in the section titled “Risk Factors” in the
final prospectus related to the public offering filed with the
Chief Financial Officer
For Cortexyme, Inc.